Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Identification of peracetylated quercetin as a selective 12-lipoxygenase pathway inhibitor in human platelets

Marco S Doucet, Jean-Luc Jougleux, Samuel J Poirier, Marc Cormier, Jacob L Leger, Marc E Surette, Nicolas Pichaud, Mohamed Touaibia and Luc H Boudreau
Molecular Pharmacology November 7, 2018, mol.118.113480; DOI: https://doi.org/10.1124/mol.118.113480
Marco S Doucet
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Luc Jougleux
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel J Poirier
2 Universite Laval
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Cormier
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob L Leger
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc E Surette
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Pichaud
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Touaibia
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luc H Boudreau
1 Universite de Moncton;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The inflammatory response is necessary for the host's defense against pathogens; however, uncontrolled or unregulated production of eicosanoids has been associated with several types of chronic inflammatory diseases. Thus, it is not surprising that enzymes implicated in the production of eicosanoids have been strategically targeted for potential therapeutic approaches. The 12-hydroxyeicosatetraenoic acid (12(S)-HETE) lipid mediator is among inflammatory molecules that are abundantly produced in various diseases and is primarily biosynthesized via the 12(S)-lipoxygenase (12-LO) pathway. The abundance of 12(S)-HETE and its contribution to several chronic inflammatory diseases have been well studied over the last few years. While most developed compounds primarily target the 5-lipoxygenase (5-LO) or the cyclooxygenase (COX) pathways, very few compounds selectively inhibiting the 12-LO pathway are known. In this study, we examined whether the distribution of hydroxyl groups among flavones could influence their potency as 12-LO inhibitors. Using human platelets, HEK293 cell line expressing 5-LO and human polymorphonuclear leukocytes we investigated the effects of these compounds on several inflammatory pathways, namely the 12-LO, 5-LO and COX. Using high-resolution respirometry and flow cytometry, we also evaluated some normal cell functions that could be modulated by our compounds. We identified a peracetylated quercetin (compound 6) that exert potent inhibitory activity towards the platelet 12-LO pathway (IC50 = 1.53 μM) while having a lesser affinity towards the COX pathway. This study characterizes the peracetylated quercetin (compound 6) as a more selective platelet-type 12-LO inhibitor than baicalein, with no measurable non-targeted effects on the platelet's activation or overall cell's oxygen consumption.

  • Anti-inflammatory drugs
  • Eicosanoids
  • Flavonoids
  • Inflammation
  • Leukotrienes
  • Platelets
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 103 (2)
Molecular Pharmacology
Vol. 103, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of peracetylated quercetin as a selective 12-lipoxygenase pathway inhibitor in human platelets
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Identification of peracetylated quercetin as a selective 12-lipoxygenase pathway inhibitor in human platelets

Marco S Doucet, Jean-Luc Jougleux, Samuel J Poirier, Marc Cormier, Jacob L Leger, Marc E Surette, Nicolas Pichaud, Mohamed Touaibia and Luc H Boudreau
Molecular Pharmacology November 7, 2018, mol.118.113480; DOI: https://doi.org/10.1124/mol.118.113480

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Identification of peracetylated quercetin as a selective 12-lipoxygenase pathway inhibitor in human platelets

Marco S Doucet, Jean-Luc Jougleux, Samuel J Poirier, Marc Cormier, Jacob L Leger, Marc E Surette, Nicolas Pichaud, Mohamed Touaibia and Luc H Boudreau
Molecular Pharmacology November 7, 2018, mol.118.113480; DOI: https://doi.org/10.1124/mol.118.113480
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics